News

VitalStream Offers Continuous Hemodynamic Monitoring Solution Amid IV Fluid Shortage

Caretaker Medical, a pioneer in advanced hemodynamic monitoring technology, is highlighting the critical role of its VitalStream solution in addressing the ongoing IV fluid shortage caused by Hurricane Helene. As healthcare providers face challenges in maintaining continuous blood pressure monitoring due to the limited availability of Baxter IV fluids, VitalStream offers a reliable and innovative alternative.

VitalStream provides continuous hemodynamic monitoring without the need for invasive arterial lines or continuous IV fluid infusion. This groundbreaking technology eliminates the reliance on IV fluids for blood pressure measurement, offering significant advantages during times of supply shortages. By providing real-time insights into a patient’s response to fluids, VitalStream can potentially reduce the overall need for IV fluid administration.

“The IV fluid shortage has created a significant challenge for healthcare providers across the country,” said Johnny Mann, VP Sales and Marketing at Caretaker Medical. “VitalStream offers a valuable solution by enabling continuous hemodynamic monitoring without the need for invasive lines or constant IV fluid infusion. This technology can help ensure patient safety and optimize fluid management during these challenging times.”

Caretaker Medical will be showcasing VitalStream at the upcoming American Society of Anesthesiologists (ASA) Conference in Philadelphia from October 19-21. Attendees will have the opportunity to learn more about this innovative technology and its potential benefits in addressing the current IV fluid shortage.

Learn more here.

Recent News

10/28/2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s common stock is expected to commence trading on The Nasdaq Capital Market under the new ticker symbol “AZR” on October 29, 2026. Azora has also launched …

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …

10/26/2026

ATCC Selected by ARPA-H to Support Next-Generation BioStabilization Technologies

ATCC has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an affiliate to provide independent verification and validation (IV&V) for its BioStabilization Systems (BoSS) program. Through this program, BoSS is taking the “200-degree leap,” from -196°C toward room temperature, to make life-saving cell therapies as easy to store and ship as …